Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 10, 2021
Discovery & Translation

New approaches to HIV prevention; plus Abpro, Capsida and more

BioCentury’s roundup of translational news
BioCentury | Jun 23, 2020
Distillery Therapeutics

An HIV vaccine stimulating T cell and antibody responses

BioCentury | Oct 25, 2019
Tools & Techniques

Gladstone, Xyphos target universal CARs to latent HIV

Gladstone, Xyphos target latent HIV with universal CARs to control safety, prevent escape
BioCentury | Aug 29, 2019
Distillery Therapeutics

Cytomegalovirus vectors could form the backbone of an HIV vaccine

BioCentury | Mar 4, 2019
Distillery Therapeutics

gp120-binding bNAbs for HIV

BioCentury | Dec 19, 2018
Distillery Therapeutics

Infectious disease

Items per page:
1 - 10 of 61